HONG KONG – With Thursday's nod for Tyvyt (sintilimab injection), a core asset of HKEX-listed Innovent Biologics Inc. to treat classical Hodgkin lymphoma, either relapsed or refractory after two or more lines of systemic chemotherapy, Chinese regulators have approved two homegrown anti-PD-1 monoclonal antibodies in little more than a week. Read More
HONG KONG – Five years into the partnership with Eli Lilly and Co., an amendment in late December to their license agreement lets Hutchison China Meditech Ltd. (Chi-Med) take a larger role in the development and commercialization of fruquintinib in China. Read More
BRISBANE, Australia – Australian researchers are using artificial intelligence (AI) to diagnose medical conditions ranging from breast cancer to post-traumatic stress disorder (PTSD) more quickly than ever before. Read More
HONG KONG – With an NDA for tislelizumab currently under review at the National Medical Products Agency (NMPA) for relapsed or refractory classical Hodgkin lymphoma, China biotech Beigene Ltd. started enrolling patients into two global phase III trials testing the PD-1-inhibiting antibody in gastric cancer and esophageal squamous cell carcinoma (ESCC). Read More
"Let me tell you about the very rich. They are different from you and me," F. Scott Fitzgerald wrote in his short story "All the Sad Young Men," to which Ernest Hemingway had a character in "The Snows of Kilimanjaro" reply "Yes, they have more money." Read More
TAIPEI, Taiwan – Taiwan startup Sinew Pharma Inc. is developing what it hopes will be a first-in-class drug to treat nonalcoholic steatohepatitis (NASH). With an investigational new drug (IND) approval by the U.S. FDA under its belt, Sinew plans to advance its core product to a phase IIb study next year. Read More
